Pomdoctor Limited (POM) fair value analysis
Nasdaq · Updated 2026-10-19
POM price how computed
Valuation status
Reports in CNYPOM reports its results in CNY while its shares trade in US dollars.
Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for POM until same-currency inputs are available. Price and market cap below are in US dollars; revenue and EPS are shown in CNY.
- Last price
- $0.92
- Sector
- Healthcare
- 12-month range
- $0.55–$109.62
- Market cap
- $7.9M
- From 52-week high
- -99.2%
- Shares outstanding
- 8.59M
- Rank in Healthcare by quality score
- #290 of 301
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-10-16.
Pomdoctor Limited is a healthcare company listed on Nasdaq that specializes in pomegranate-based health and wellness products. The company operates primarily in the United States and international markets.
POM currently ranks #290 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
Revenue and EPS are shown in CNY; the trailing P/E is omitted because an EPS in CNY against a US-dollar share price would mislead.
- Market cap
- $7.9M
- Gross margin
- 13.7%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- -33.2%
- Shares outstanding
- 8.59M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 42 · neutral
- 50-day average
- $0.87
- 200-day average
- $3.13
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Earnings how computed
- Last 2 quarters vs consensus
- 0 beat, 2 missed
- Quarter by quarter
- 2025-09 ▼ miss
2024-12 ▼ miss
What our data shows for POM
- Shares are trading in the lower third of their 12-month price range of $0.55–$109.62.
- The 14-day relative strength index sits at a neutral 42.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- POM's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the POM conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — POM's revenue growth band shifted to declining this week, moving from a neutral position. TickrTrends' derived indicators for the Healthcare sector stock reflect this change as part of the ongoing monitoring process. The valuation verdict remains in an awaiting status pending fuller assessment.
- 2026-10-05 — TickrTrends' derived indicators for POM in the Healthcare sector show a shift this week in gross-margin trend, which has moved from expanding to contracting. The valuation verdict remains awaiting full valuation as additional analysis continues.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is POM stock undervalued?
POM reports its results in CNY while its shares trade in US dollars. Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for POM until same-currency inputs are available.
What is POM's TickrTrends verdict?
POM is currently marked 'Reports in CNY' - no verdict is published on inputs in two different currencies.
How does POM compare to other Healthcare stocks?
POM ranks #290 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is POM overbought or oversold?
POM's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does POM usually beat earnings estimates?
Over its last 2 reported quarters POM beat the consensus estimate 0 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.